Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Company Overview

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages.

Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.

Key Stats

• Today's Range: $7.54 to $7.87
• 50-Day Range: $4.19 to $7.74
• 52-Week Range: $3.50 to $12.40
• Volume: 488,871 shs
• Average Volume: 2.52 million shs
• Market Capitalization: $473.08 million
• P/E Ratio: 21.50
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Hold

Monte Rosa Therapeutics Stock Analysis - MarketRank™

Monte Rosa Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 447th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Monte Rosa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Monte Rosa Therapeutics has a consensus price target of $15.33, representing about 100.2% upside from its current price of $7.66.

Amount of Analyst Coverage

Monte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monte Rosa Therapeutics is 21.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.46.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monte Rosa Therapeutics is 21.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.66.

Price to Book Value per Share Ratio

Monte Rosa Therapeutics has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.84% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monte Rosa Therapeutics does not currently pay a dividend.

Dividend Growth

Monte Rosa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.84% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Monte Rosa Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for GLUE on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

MarketBeat Follows

1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Monte Rosa Therapeutics is held by insiders.

Percentage Held by Institutions

79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLUE Stock Analysis - Frequently Asked Questions

How have GLUE shares performed this year?

Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE stock has increased by 10.4% and is now trading at $7.66.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The company earned $23.19 million during the quarter, compared to analyst estimates of $7.23 million. Monte Rosa Therapeutics had a trailing twelve-month return on equity of 9.95% and a net margin of 13.58%.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monte Rosa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLUE
• CIK: 1826457
• Web: www.monterosatx.com
• Phone: 617-949-2643
• Fax: N/A
• Employees: 90
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Monte Rosa Therapeutics: $15.33
• High Price Target: $19.00
• Low Price Target: $10.00
• Potential Upside/Downside: +98.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.36
• Trailing P/E Ratio: 21.43
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.70 million
• Net Margins: 13.58%
• Pretax Margin: 15.97%
• Return on Equity: 9.95%
• Return on Assets: 6.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.16
• Quick Ratio: 7.16

Sales & Book Value

• Annual Sales: $177.99 million
• Price / Sales: 2.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.63 per share
• Price / Book: 2.12

Miscellaneous

• Outstanding Shares: 61,759,000
• Free Float: 57,745,000
• Market Cap: $476.16 million
• Optionable: Optionable
• Beta: 1.54